Connect your AI

Sight Sciences, Inc. SGHT Total Equity

Total Equity at other companies

GlaukosGKOS

$670.93M-12.2%

AbbVieABBV

-$6.66B-569%

Schering-PloughSGP

$250.11M+463%

Bausch + LombBLCO

$6.38B+0.3%

Tarsus Pharmaceuticals, Inc.TARS

$348.95M+1.9%

Johnson & JohnsonJNJ

——

Other financials

Income statement

Revenue$19.7M+12.5%

Gross profit$17.0M+12.5%

Operating income-$12.4M+10.4%

Net income-$13.0M+8.3%

EPS (diluted)-$0.24+14.3%

Balance sheet

Cash & equivalents$85.0M-21.9%

Total debt$40.9M+1.1%

Total assets$109.7M-15.4%

Cash flow

Operating cash flow-$7.0M+39.4%

CapEx$60.0K—

Free cash flow-$7.1M+38.9%

Valuation

Market cap$294.9M+35.0%

Enterprise value$250.83M+59.0%

P/S3.7×+0.8×

Profitability

Gross margin86.2%+0.5pp

Operating margin-44.8%-10.2pp

Net margin-46.8%-9.6pp

FCF margin-31.9%+0.2pp

Returns & leverage

Return on equity-56.6%+4.3pp

Debt / equity0.8×+0.2×

Current ratio5.9×-4.6×

Where this comes from

Reported directly by Sight Sciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sight Sciences, Inc.'s total equity?: Sight Sciences, Inc. (SGHT) reported total equity of $53.9M in Q1 2026.
How has Sight Sciences, Inc.'s total equity changed year-over-year?: Sight Sciences, Inc.'s total equity decreased by 30.6% year-over-year, from $77.63M to $53.9M.
What is the long-term trend for Sight Sciences, Inc.'s total equity?: Over 5 years (2020 to 2025), Sight Sciences, Inc.'s total equity has grown at a -6.4% compound annual growth rate (CAGR), from -$88.85M to $63.94M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.